Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares


The MarketWatch News Department was not involved in the creation of this content.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC acted as joint book-running managers in the offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. acted as passive bookrunners in the offering.

Stoke intends to use the net proceeds from the proposed offering, together with its

Read More

Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020


Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020

  • Pre-clinical safety data show no adverse or off-target effects and targeted biodistribution of the company’s wholly owned gene-silencing candidate SLN360

  • Profile supports SLN360’s progression to in-human testing for the treatment of elevated lipoprotein(a), an independent risk factor for premature heart disease, heart attack and stroke

16 November 2020

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, has presented positive pre-clinical safety data for its wholly owned lead product candidate, SLN360, at the American Heart Association (AHA)’s virtual Scientific Sessions 2020, being held 14-16 November.1 The results, available here, demonstrated that the potent and sustained reduction of lipoprotein(a) – Lp(a)

Read More